Is lurbinectedin used with immunotherapy?
Yes, lurbinectedin (brand name Zepzelca) is FDA-approved for use in combination with atezolizumab, an anti-PD-L1 immunotherapy, for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy.[1]
This approval came in 2024 based on the phase III IMforte trial, which showed the combo improved overall survival (median 15.1 months vs. 13.0 months with atezolizumab alone) and progression-free survival compared to immunotherapy monotherapy.[2][1]
How does the lurbinectedin-atezolizumab combo work?
Lurbinectedin inhibits DNA repair in cancer cells by targeting transcription factors, while atezolizumab blocks PD-L1 to boost T-cell immune response. Together, they enhance antitumor activity in platinum-resistant SCLC, a cancer with limited options post-chemo.[2]
What trial data supports this combination?
IMforte enrolled 511 patients with relapsed ES-SCLC. Key results:
- Hazard ratio for death: 0.79 (95% CI 0.65-0.96).
- Manageable toxicity; grade ≥3 adverse events similar between arms (around 60%).[2]
Earlier phase Ib/II trials also tested the combo safely, paving the way for phase III.[3]
Are there other immunotherapy combinations with lurbinectedin?
No other FDA-approved immunotherapy combos exist for lurbinectedin. Ongoing trials explore it with pembrolizumab (anti-PD-1) in SCLC and other solid tumors, but results are pending.[4]
It's not approved with chemo-immunotherapy like carboplatin-etoposide-atezolizumab; that's a separate first-line regimen.
Who gets this treatment and when?
Reserved for second-line or later use in ES-SCLC after platinum failure. Not for first-line or other SCLC subtypes without progression.[1]
What about patents or generics?
Lurbinectedin patents extend to 2031 in the US, with no generics approved. Jazz Pharmaceuticals holds exclusivity; check DrugPatentWatch.com for litigation updates.[5]
[1]: FDA.gov - Approval Summary: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lurbinectedin-atezolizumab-extensive-stage-small-cell-lung-cancer
[2]: NEJM - IMforte Trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2403075
[3]: JCO - Phase Ib/II Data: https://ascopubs.org/doi/10.1200/JCO.21.01308
[4]: ClinicalTrials.gov - Search "lurbinectedin pembrolizumab"
[5]: DrugPatentWatch.com - Lurbinectedin: https://www.drugpatentwatch.com/p/tradename/ZEPELCA